HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SD-3211, a novel benzothiazine calcium antagonist, alone and in combination with a beta-adrenoceptor antagonist, produces antihypertensive effects without affecting heart rate and atrioventricular conduction in conscious renal hypertensive dogs.

Abstract
We compared the effects of SD-3211, a novel calcium antagonist, on blood pressure, heart rate, and atrioventricular conduction with those of diltiazem using conscious renal hypertensive dogs (one-kidney, one-clip type). We also examined the combined effects of these calcium antagonists with a beta-adrenoceptor antagonist, propranolol, on these variables. Oral administration of SD-3211 (1.25, 2.5, and 5 mg/kg) resulted in a dose-dependent decrease in blood pressure without affecting heart rate. SD-3211 at all three doses significantly decreased systolic blood pressure. At 2.5 and 5 mg/kg the compound elicited significant decreases in mean blood pressure and diastolic blood pressure. Hypotension obtained with the highest dose of SD-3211 lasted for at least 9 h. No significant alteration in PR interval was observed in electrocardiograms after administration of SD-3211. Diltiazem, given orally at doses of 2.5 and 5 mg/kg but not 1.25 mg/kg, produced significant hypotension with little change in heart rate. The duration of hypotension induced by the highest dose of diltiazem was only 3 h. Diltiazem prolonged PR interval in a dose-dependent manner, causing second-degree atrioventricular block in some dogs. Combined administration of SD-3211 or diltiazem (2.5 mg/kg) with propranolol (30 mg/kg) resulted in enhanced hypotension with no alteration in heart rate. SD-3211 plus propranolol had little effect on the PR interval, whereas diltiazem plus propranolol caused a markedly enhanced prolongation. These results indicate that SD-3211 is an antihypertensive agent with long-lasting action and little effect on heart rate and atrioventricular conduction and, when administered alone or in combination with propranolol, may be useful in the treatment of hypertension.
AuthorsM Kageyama, K Nishimura, T Takada, N Miyawaki, H Yamauchi
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 17 Issue 1 Pg. 102-7 (Jan 1991) ISSN: 0160-2446 [Print] United States
PMID1708042 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Adrenergic beta-Antagonists
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Thiazoles
  • Propranolol
  • sesamodil
  • Diltiazem
Topics
  • Administration, Oral
  • Adrenergic beta-Antagonists (pharmacology)
  • Animals
  • Antihypertensive Agents (administration & dosage, pharmacology)
  • Atrioventricular Node (drug effects, physiology)
  • Blood Pressure (drug effects)
  • Calcium Channel Blockers (administration & dosage, pharmacology)
  • Diltiazem (administration & dosage, pharmacology)
  • Dogs
  • Drug Therapy, Combination
  • Electrocardiography (drug effects)
  • Heart Rate (drug effects)
  • Hypertension, Renal (drug therapy, physiopathology)
  • Male
  • Propranolol (pharmacology)
  • Thiazoles (administration & dosage, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: